Mural Oncology (NASDAQ:MURA – Get Free Report) released its earnings results on Tuesday. The company reported ($2.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05), RTT News reports. During the same period in the prior year, the company posted ($3.57) earnings per share.
Mural Oncology Stock Performance
Shares of Mural Oncology stock opened at $3.80 on Wednesday. The firm has a fifty day moving average of $3.84 and a two-hundred day moving average of $3.58. The stock has a market capitalization of $64.68 million, a price-to-earnings ratio of -0.42 and a beta of 3.66. Mural Oncology has a 52 week low of $2.87 and a 52 week high of $5.38.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Mural Oncology in a research report on Wednesday.
Mural Oncology Company Profile
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
See Also
- Five stocks we like better than Mural Oncology
- How is Compound Interest Calculated?
- Samsara Stock Plunges, But Technicals Flash a Buy Signal
- What is Put Option Volume?
- 3 Retail Giants React to Tariffs—What It Means for Consumers
- How to Find Undervalued Stocks
- Rockwell Automation Poised to Gain From U.S. Tariffs & Onshoring
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
